

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/507,316	09/10/2004	Akira Tsuboyama	03500.017248	4017
	7590 05/04/200 CELLA HARPER &	EXAMINER		
30 ROCKEFEI		YAMNITZKY, MARIE ROSE		
NEW YORK, NY 10112			ART UNIT	PAPER NUMBER
			1774	
			MAIL DATE	DELIVERY MODE
			05/04/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/507,316	TSUBOYAMA ET AL.			
Office Action Summary	Examiner	Art Unit			
	Marie R. Yamnitzky	1774			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATIO (36(a). In no event, however, may a reply be ti will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDON	N. mely filed n the mailing date of this communication. ED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 10 S	Sep 2004, 23 Nov 2004 & 22 Dec	<u>2004</u> .			
2a) ☐ This action is FINAL . 2b) ☑ This	This action is FINAL . 2b)⊠ This action is non-final.				
•	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
 4) Claim(s) 1-9 is/are pending in the application. 4a) Of the above claim(s) is/are withdra 5) Claim(s) is/are allowed. 6) Claim(s) 1-9 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or 		•			
Application Papers	\				
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E	cepted or b) objected to by the drawing(s) be held in abeyance. Settion is required if the drawing(s) is o	ee 37 CFR 1.85(a). bjected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summar Paper No(s)/Mail t	Date			
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 10 Sep 2004, 23 Nov 2004 and 2	5)	Patent Application			

Application/Control Number: 10/507,316

Art Unit: 1774

1. Claims 1-5 and 7-9 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which

Page 2

applicant regards as the invention.

Lines 14-16 of claim 1 recite "the heterocyclic rings may have a substituent selected from the group consisting of...". It is not clear if the heterocyclic rings may have a substituent other than those set forth in the group.

It is not clear if general formula (2) as set forth in claim 3 is considered to be a subset of general formula (1) as set forth in claim 1, or if general formula (2) is in addition to general formula (1). If formula (2) is supposed to be a subset of formula (1), it is not clear how the possibility of an isoquinoline ring, or an isoquinoline ring having one or more C-H replaced with nitrogen atom(s), for heterocyclic ring C is within the scope of heterocyclic ring (A), particularly if the substituents for the heterocyclic rings are limited to those set forth in the group in claim 1.

It is not clear if general formulae (3) and (4) as set forth in claims 4 and 5, respectively, are considered to be subsets of general formula (2) as set forth in claim 3, or if general formulae (3) and (4) are in addition to general formula (2). If formulae (3) and (4) are supposed to be subsets of formula (2), it is not clear how the ring structure of three fused rings is within the scope of formula (2) given the definition of the substituent as set forth in claim 3.

Claims 7 and 8: Clarification is required as to whether the recited light emission lifetime pertains to the device as a whole, or to the compound having a partial structure represented by general formula (1).

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the

basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on

sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this

international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United

States and was published under Article 21(2) of such treaty in the English language.

3. Claims 1-4 and 7-9 are rejected under 35 U.S.C. 102(b) as being anticipated by JP 2-

8288.

In particular, see the three formulae at the bottom of the second page and the formula at

the top of the third page of the Japanese language document, see the Figure, and see the English

language abstract.

The prior art discloses metal complexes of these formulae wherein M may be copper.

Subject to claim interpretation, copper complexes of these formulae meet the limitations of a

metal coordination compound having a partial structure represented by present general formula

(1) or (2). A copper complex of the first or third formula on the second page of the Japanese

language document further meets the limitations of a metal coordination compound having a

partial structure represented by present general formula (3).

With respect to the light emission lifetime limitation of present claims 7 and 8, it is the

examiner's position that it is reasonable to expect that copper complexes of the prior art formulae

Art Unit: 1774

inherently meet the limitation given the similarity between the prior art complexes and the copper complexes exemplified in the present disclosure.

4. Claims 1 and 9 are rejected under 35 U.S.C. 102(b) as being anticipated by Enokida et al. (US 6,001,284).

In particular, see column 1, lines 8-27 and c. 15, l. 1-23. The metal complex compound copper bis(8-hydroxyquinolinate) is named at c. 15, l. 22-23 for use in a light-emitting layer of an organic EL device. Copper bis(8-hydroxyquinolinate) is a metal coordination compound having a partial structure represented by present general formula (1).

5. Claims 1-4 and 6-9 are rejected under 35 U.S.C. 102(e) as being anticipated by Brunner et al. (US 2002/0079830 A1).

See the whole publication. In particular, see paragraphs [0001]-[0002], [0004]-[0011] and [0019]-[0020] and claims 1-5, 9 and 10.

Subject to claim interpretation, electroluminescent materials according to the prior art in which at least one of the at least two metal chelates is a Cu chelate comprising a chelating moiety selected from moieties of the general formulae set forth in paragraphs [0006]-[0007] meet the limitations of a metal coordination compound having a partial structure represented by present general formula (1) or (2). An electroluminescent material according to the prior art in which at least one of the metal chelates is a Cu chelate comprising a chelating moiety of the second formula in paragraph [0006] further meets the limitations of a metal coordination compound

Application/Control Number: 10/507,316 Page 5

Art Unit: 1774

having a partial structure represented by present general formula (3). An electroluminescent material according to the prior art in which at least one of the metal chelates is a Cu chelate comprising a chelating moiety of the first or third formula in paragraph [0006] further meets the limitations of a metal coordination compound having a partial structure represented by present general formula (5).

With respect to the light emission lifetime limitation of present claims 7 and 8, it is the examiner's position that it is reasonable to expect that copper complexes of the prior art formulae inherently meet the limitation given the similarity between the prior art complexes and the copper complexes exemplified in the present disclosure.

- 6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 7. Claims 1-9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Brunner et al. (US 2002/0079830 A1) as applied to claims 1-4 and 6-9 above, and for the further reasons set forth below.

The general formulae for the chelating moieties as shown in paragraphs [0006]-[0007] are unsubstituted, but Brunner et al. teach that the chelating moieties can be substituted or unsubstituted. For example, see paragraphs [0006], [0008] and [0011]. Substituents taught in

Application/Control Number: 10/507,316

Art Unit: 1774

paragraph [0011] include substituents within the scope of substituents specified in the present

claims. It would have been prima facie obvious to one of ordinary skill in the art at the time of

the invention to make and use substituted derivatives of the chelating moieties of the general

formulae set forth in paragraphs [0006]-[0007]. Regarding the compound having a partial

structure represented by general formula (4) as defined in present claim 5, such compounds are

encompassed by the prior art wherein the chelating moiety of the second general formula in

paragraph [0006] may be substituted by substituents disclosed in paragraph [0011]. Absent a

showing of superior/unexpected results commensurate in scope with the claimed subject matter,

it is the examiner's position that it would have been within the level of ordinary skill of a worker

in the art at the time of the invention to determine suitable and optimum substituents and patterns

of substitution for the prior art chelating moieties.

8. Miscellaneous:

In line 3 of claim 1, "electrode" should read --electrodes--.

9. Any inquiry concerning this communication should be directed to Marie R. Yamnitzky at

telephone number (571) 272-1531. The examiner works a flexible schedule but can generally be

reached at this number from 7:00 a.m. to 3:30 p.m. Monday-Friday.

The current fax number for all official faxes is (571) 273-8300. (Unofficial faxes to be

sent directly to examiner Yamnitzky can be sent to (571) 273-1531.)

MRY

April 28, 2007

MARIE YAMNITZKY

Marie R. Yamnites

Page 6

PRIMARY EXAMINER

1774